“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Saturday, August 30, 2025

Astellas Pharma US


Astellas Pharma US products

AmBisome (amphotericin B liposomal) — Antifungal therapy for serious systemic fungal infections
Astagraf XL (tacrolimus extended-release) — Immunosuppression to prevent organ transplant rejection
Cresemba (isavuconazonium) — Treatment of invasive fungal infections
Izervay (avacincaptad pegol) — Prevents geographic atrophy in age-related macular degeneration
Lexiscan (regadenoson) — Pharmacologic stress agent for cardiac imaging
Myrbetriq (mirabegron) — Treatment of overactive bladder
Mycamine (micafungin) — Antifungal for systemic infections (echinocandin class)
Padcev (enfortumab vedotin) — Antibody-drug conjugate for urothelial cancer
Prograf (tacrolimus) — Standard immunosuppressive agent for transplant rejection prevention
Vesicare (solifenacin) — Overactive bladder management
Veoza / Veozah (fezolinetant) — Oral NK₃ antagonist for menopausal hot flashes
Vyloy (zolbetuximab) — First-line treatment of CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma
Xospata (gilteritinib) — FLT3-mutated acute myeloid leukemia therapy
Xtandi (enzalutamide) — Prostate cancer therapy (hormone-sensitive and metastatic settings)



on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)